Ivermectin Found to Save Lives Better Than Remdesivir
Those trying to stop use of remdesivir in hospitals should know about this study
The controversy over use of ivermectin has continued despite massive evidence that it is effective as a prophylactic and treatment for COVID. The public health establishment and mainstream media remain stubbornly opposed to its use.
Many hospitals have been using the expensive remdesivir in their protocols while refusing use of ivermectin by families trying to save the lives of loved ones. Remdesivir has a number of very bad side effects.
Now comes a published medical article that found IVM is better at saving lives. The study accessed medical records from a global network among 28 countries with over 400 million patients. Thus the researchers were able to get a large group of patients with COVID who used IVM, and matched them to those using remdesivir taking into account many factors affecting health outcomes. The article says it looked at patients in the US.
Because the published article is short, I give it all below. I emphasize that the statistical analysis found an extremely significant benefit for saving lives with IVM as evidenced by an extremely low P value. Note that the patient records were from before omicron became widespread.
The article was published in the International Journal of Infectious Diseases this month and was written by four physicians from the University of Miami. The title is: Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database.
Here is the full article:
Purpose
To evaluate the difference in mortality of patients treated with ivermectin vs patients treated with remdesivir with COVID-19 in United States using TriNetX Research network, a federated EMR network of over 44 healthcare organizations and 68 million patients from US, from 2009-2021.
Methods & Materials
We retrospectively identified adults (≥18 years) with a recorded COVID-19 infection between January 1, 2020 and July 11, 2021. We compared those with recorded use of ivermectin, but not remdesivir, against those with recorded use of remdesivir, but not ivermectin. We controlled for the following demographics, comorbidities, and treatments that may affect COVID-19 survival outcomes: age, gender, race, ethnicity, nicotine use diabetes mellitus, obesity, chronic lower respiratory disease, ischemic heart diseases, tocilizumab, glucocorticoids, or ventilator use. We measured association with mortality as the primary outcome, with significance assessed at p<0.05.
Results
There were a total of 1,761,060 possible COVID-19 patients based on ICD-10 diagnostic terms and confirmatory lab results. Prior to controlling, our analysis yielded 41,608 patients who had COVID-19 resulting in two unique cohorts that were treated with either ivermectin (1,072) or remdesivir (40,536). Within the ivermectin cohort, average age was 51.9 + 17.8 years, 43% were male, 60% had glucocorticoids and 1% required ventilator support. In the remdesivir cohort, average age was 62.0 + 16.0 years, 54% were male, 64% had glucocorticoids and 2% required ventilator support. After using propensity score matching and adjusting for potential confounders, ivermectin was associated with reduced mortality vs remdesivir (OR 0.308, 95% CI (0.198,0.479)),Risk Difference -5.224%, CI (-7.079%,-3.369%), p <0.0001.
Conclusion
Ivermectin use was associated with decreased mortality in patients with COVID-19 compared to remdesivir. To our knowledge, this is the largest association study of patients with COVID-19, mortality and ivermectin. Further double-blinded placebo-controlled RCTs with large samples are required for definite conclusion. In the future, if more publications are published with the similar result to the current analyses, the certainty of evidence will increase. [In my opinion, there is already sufficient evidence that IVM is safe and effective for use to prevent and treat COVID.]
Unfortunately, now the authors want to disavow their own research:
Jose Gonzales Zamora
@JoseGonzalesZa1
Replying to @PierreKory
I am ONE of the authors of the study. This "retrospective" study looks for ASSOCIATION, not causality. Now that we have randomized clinical trials, we can say with certainty that IVERMECTIN DOES NOT WORK AT ALL FOR COVID. I recommend to read the conclusions of the abstract.
1:22 PM · Mar 3, 2022·Twitter Web App
460 Retweets 168 Quote Tweets 2,366 Likes
https://twitter.com/josegonzalesza1/status/1499450061025157120?s=12
It’s clear someone “got to them”.
Robert Clark
Unfortunately it appears this study was a ruse to make ivermectin proponents look bad. The abstract was not peer-reviewed and has been redacted and denounced by it's own authors. Yet still remains in the International Journal of Infectious Diseases, with no mention of it being redacted. Shady behavior by both the journal and the authors I'm afraid.